853 related articles for article (PubMed ID: 21454009)
1. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Eur Urol; 2011 Jun; 59(6):1009-18. PubMed ID: 21454009
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines].
Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Actas Urol Esp; 2012 Sep; 36(8):449-60. PubMed ID: 22386114
[TBL] [Abstract][Full Text] [Related]
3. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
[TBL] [Abstract][Full Text] [Related]
4. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer.
Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA
Eur Urol; 2009 Apr; 55(4):815-25. PubMed ID: 19157687
[TBL] [Abstract][Full Text] [Related]
5. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.
Kulkarni GS; Hakenberg OW; Gschwend JE; Thalmann G; Kassouf W; Kamat A; Zlotta A
Eur Urol; 2010 Jan; 57(1):60-70. PubMed ID: 19740595
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.
Witjes JA; Compérat E; Cowan NC; De Santis M; Gakis G; Lebret T; Ribal MJ; Van der Heijden AG; Sherif A;
Eur Urol; 2014 Apr; 65(4):778-92. PubMed ID: 24373477
[TBL] [Abstract][Full Text] [Related]
7. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
Witjes JA; Bruins HM; Cathomas R; Compérat EM; Cowan NC; Gakis G; Hernández V; Linares Espinós E; Lorch A; Neuzillet Y; Rouanne M; Thalmann GN; Veskimäe E; Ribal MJ; van der Heijden AG
Eur Urol; 2021 Jan; 79(1):82-104. PubMed ID: 32360052
[TBL] [Abstract][Full Text] [Related]
8. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
Izawa JI; Chin JL; Winquist E
Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
12. [European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].
Rouprêt M; Zigeuner R; Palou J; Boehle A; Kaasinen E; Sylvester R; Babjuk M; Oosterlinck W;
Actas Urol Esp; 2012 Jan; 36(1):2-14. PubMed ID: 22036956
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
14. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
[TBL] [Abstract][Full Text] [Related]
16. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
18. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
19. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
20. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]